Genotypic resistance testing of antiretrovirals in HIV
Medical Services Advisory Committee
Record ID 32006000290
English
Authors' objectives:
This assessment was undertaken to provide the broadest possible advice regarding the safety, effectiveness and cost-effectiveness of genotypic resistance testing for antiretrovirals in patients infected with human immunodeficiency virus (HIV).
Authors' recommendations:
MSAC found that genotypic resistance testing of antiretrovirals in HIV appeared to be safe and leads to changes in clinical management but there is insufficient evidence on effectiveness and cost-effectiveness to support Medicare funding.
Authors' methods:
Systematic Review
Details
Project Status:
Completed
URL for project:
http://www.msac.gov.au/reports.htm
Year Published:
2009
URL for published report:
http://www.msac.gov.au/internet/msac/publishing.nsf/Content/1127-public
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Australia
MeSH Terms
- Drug Resistance, Viral
- Genotype
- Anti-Retroviral Agents
- HIV Infections
- Mutation
- HIV
Contact
Organisation Name:
Medical Services Advisory Committee
Contact Address:
MSAC (MDP 107), GPO Box 9848, Canberra, ACT 2601, Australia. Tel: +61 2 6289 6811; Fax: +61 2 6289 8799.
Contact Name:
msac.secretariat@health.gov.au
Contact Email:
msac.secretariat@health.gov.au
Copyright:
Medical Services Advisory Committee (MSAC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.